Updated

Updated · CNBC · Jul 31

Replimune Shares Jump 94% After FDA Panel Backs RP1 Skin Cancer Trial

Updated

Updated · CNBC · Jul 31

Replimune Shares Jump 94% After FDA Panel Backs RP1 Skin Cancer Trial

3 articles · Updated · CNBC · Jul 31

Replimune rose more than 94% in midday trading after an FDA advisory panel voted in favor of trial results for its RP1 treatment in a type of skin cancer.
Wedbush upgraded the clinical-stage biotech to outperform from neutral following the panel decision, adding to investor optimism around the program.
The move extended an earlier rally of more than 130% in premarket trading, showing the favorable FDA review remained the main driver of the stock's gains through the session.

Sources

Left67%

Center33%

Replimune Group Shares Soar 94% After FDA Panel Backs RP1 Skin Cancer Drug Trial

Replimune surges after FDA advisers back skin cancer drug | Reuters

Replimune Group Shares Soar Over 130% Premarket After FDA Panel Favors RP1 Skin Cancer Drug Trial

With an FDA decision just days away, could past trial concerns still derail this biotech company's massive market surge?

As AI infrastructure spending drains free cash flow, will tech giants' massive financial bets become a historic misstep?

Could shifting search engine behaviors permanently cripple the vital referral traffic that social platforms rely on for survival?

Related Stories

Sources

5 total

Left67%

Center33%

Replimune Group Shares Soar 94% After FDA Panel Backs RP1 Skin Cancer Drug Trial

Replimune surges after FDA advisers back skin cancer drug | Reuters

Replimune Group Shares Soar Over 130% Premarket After FDA Panel Favors RP1 Skin Cancer Drug Trial

Show all 5 sources

Related Stories